In addition to the 57.9% of CRC harboring KRAS, NRAS and BRAF mutations, another 17.5% patients with genetic mutations in genes including PTEN, PIK3CA and HER2 might not benefit from anti-EGFR therapy. This evidence concerns the gene BRAF and colorectal carcinoma.